Skip to content

Enhancement of pharmacist role for the management of Chronic Obstructive Pulmonary Disease (COPD) in Pakistan

Management of COPD and other Comorbidities in COPD Patients by Dispensing Pharmaceutical Care following the Global Initiative for Chronic Obstructive Lung disease-guidelines (GOLD guidelines 2020) : A Prospective Clinical Trial.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12622000234718
Enrollment
0
Registered
2022-02-09
Start date
2023-03-01
Completion date
2023-05-01
Last updated
2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Hypothesis: Implementation of Global Initiative of Chronic Obstructive Lung disease will improve the management of COPD Purpose of study: The aim of the study is to improve COPD management by implementing standard treatment guidelines for the the provision of pharmaceutical care to the COPD patients to improve the quality of life and to improve treatment outcome. Intervention: Pharmacological intervention: Medications therapy was provided by following the GOLD guidelines against the GOLD COPD classIfication Non-Pharmacological intervention: patient counselling about disease, medications, diet and preventions, and vaccinate the COPD patients against influenza and pneumococcal infections etc. Follow up: Patients' will be examined to evaluate the impact of intervention on COPD disease management

Interventions

The study has two arms Arm 1: There will be only educational intervention provided to this group (COPD patients) by the principle investigator ( Counselling about the disease, correct use of medication and life style modification ( Diet and Exercise). This study group will receive the onging medication prescribed by the physician. Arm 2 : There will be a pharmacological intervention will be provided according to the GOLD guidelines as following step 1: The patients will be diagnosed following t

The study has two arms Arm 1: There will be only educational intervention provided to this group (COPD patients) by the principle investigator ( Counselling about the disease, correct use of medication and life style modification ( Diet and Exercise). This study group will receive the onging medication prescribed by the physician. Arm 2 : There will be a pharmacological intervention will be provided according to the GOLD guidelines as following step 1: The patients will be diagnosed following the standard procedure mentioned in GOLD guidelines. Step 2: Then pharmacological treatment will be given according to the GOLD guidelines Step 3: Educational intervention ( 30 minute face-to-face patient counselling) will be provided also as mentioned in Arm 1 Study Activities: 1: At the time of patient enrollment interventions will be provided to both groups 2: After every 2 months patients will be called for checking adherence to the interventions by interviewing the patients and by checking patient prescriptions and medications used by patients 3: The patients will be enrolled at Out patient department of ' Holy Family Hospital Rawalpindi, Pakistan' and interventions will be provided by the principle investigator 4 : The interventions will be provided only once 5: Response will be gathered after 6 months by checking disease state, patient quality of life and No. of acute exacerbation during this period of study

Sponsors

Amjad Khan
Lead SponsorIndividual

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients only attend the outpatient COPD wards, confirmed diagnosis of COPD by the hospital consultant for at least 1 year with a forced expiratory volume in 1 s (FEV1) of 30–80% of the predicted normal value, patients that hospital consultant agree that the patient is suitable for entering the trial will be included in this study.

Exclusion criteria

Patients will be excluded from the study if they will have moderate to severe learning difficulties, mobility problems, confusion, disorientation or terminal illness, congestive heart failure or if they are attending a pulmonary rehabilitation programs consulting a pulmonary nurse or clinical pharmacist in the last 6 month will be excluded.

Outcome results

None listed

Source: ANZCTR · Data processed: Jun 18, 2026